Stock listing
NASDAQ:CLYM Climb Bio, Inc. Stock
Home listing (NASDAQ) of Climb Bio, Inc.
Follow Climb Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CLYM
$9.19 USD -0.11 (-1.2%)
Close on Nov 20, 2026
- Day range
- $8.90 – $9.40 USDNov 20, 2026
- Volume
- 770,170 sharesNov 20, 2026
- Market cap
- $539.8M USDAt the close on Nov 20, 2026 · price × 58.74M shares outstanding
- 52-week range
- $1.64 – $18.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $17.07M USDMedian day 1.15M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CLYM · Home | $9.19 USD | -0.11 (-1.2%) | 770,170 | $8.94 | $9.398 | $8.90 | $9.30 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLYM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $9.19 | -0.11 | -1.2% | $8.94 | $9.398 | $8.90 | 770,170 | |
| $9.30 | -0.48 | -4.9% | $9.79 | $9.995 | $9.24 | 865,210 | |
| $9.78 | -0.16 | -1.6% | $9.95 | $10.42 | $9.37 | 593,757 | |
| $9.94 | -0.42 | -4.1% | $10.10 | $10.57 | $9.87 | 675,561 | |
| $10.36 | -0.51 | -4.7% | $10.76 | $10.99 | $10.19 | 667,579 | |
| $10.87 | -1.38 | -11.3% | $11.97 | $12.14 | $10.68 | 1,346,255 | |
| $12.25 | +0.51 | +4.3% | $11.72 | $12.44 | $11.49 | 1,663,783 | |
| $11.74 | +0.73 | +6.6% | $10.96 | $11.87 | $10.62 | 1,567,746 | |
| $11.01 | +0.72 | +7.0% | $10.50 | $11.54 | $10.28 | 1,783,649 | |
| $10.29 | +1.42 | +16.0% | $9.05 | $10.33 | $8.84 | 1,139,760 | |
| $8.87 | -0.46 | -4.9% | $8.87 | $9.20 | $8.485 | 1,435,446 | |
| $9.33 | -0.42 | -4.3% | $9.97 | $10.10 | $9.191 | 1,044,046 | |
| $9.75 | +0.01 | +0.1% | $9.86 | $10.07 | $9.56 | 887,621 | |
| $9.74 | -0.51 | -5.0% | $10.25 | $10.44 | $9.69 | 1,146,907 | |
| $10.25 | -0.08 | -0.8% | $10.29 | $10.51 | $10.02 | 708,718 | |
| $10.33 | +0.21 | +2.1% | $10.35 | $10.55 | $10.09 | 688,967 | |
| $10.12 | +0.55 | +5.7% | $9.32 | $10.13 | $9.25 | 944,697 | |
| $9.57 | +0.76 | +8.6% | $8.90 | $10.15 | $8.815 | 3,904,200 | |
| $8.81 | -1.38 | -13.5% | $9.88 | $9.99 | $8.70 | 3,381,116 | |
| $10.19 | -0.35 | -3.3% | $10.47 | $10.66 | $10.05 | 495,694 | |
| $10.54 | -0.33 | -3.0% | $10.57 | $11.23 | $10.44 | 654,057 | |
| $10.87 | +0.07 | +0.6% | $10.83 | $11.26 | $10.60 | 930,385 | |
| $10.80 | +1.07 | +11.0% | $9.84 | $10.99 | $9.84 | 1,369,064 | |
| $9.73 | -0.09 | -0.9% | $9.92 | $10.43 | $9.61 | 1,214,409 | |
| $9.82 | -1.09 | -10.0% | $10.89 | $10.91 | $9.69 | 990,300 | |
| $10.91 | +0.62 | +6.0% | $10.32 | $10.98 | $10.25 | 515,500 | |
| $10.29 | -0.02 | -0.2% | $10.19 | $10.64 | $10.09 | 987,700 | |
| $10.31 | -0.52 | -4.8% | $10.75 | $10.79 | $10.18 | 901,300 | |
| $10.83 | -0.17 | -1.5% | $10.91 | $11.15 | $10.73 | 911,600 | |
| $11.00 | +0.14 | +1.3% | $10.81 | $11.30 | $10.75 | 638,000 | |
| $10.86 | +0.15 | +1.4% | $10.55 | $11.00 | $10.27 | 1,148,800 | |
| $10.71 | +0.03 | +0.3% | $10.43 | $10.95 | $10.34 | 755,800 | |
| $10.68 | -0.37 | -3.3% | $11.12 | $11.25 | $10.64 | 953,600 | |
| $11.05 | +0.11 | +1.0% | $10.94 | $11.20 | $10.70 | 1,206,400 | |
| $10.94 | -0.13 | -1.2% | $11.29 | $11.29 | $10.73 | 1,574,900 | |
| $11.07 | -0.40 | -3.5% | $11.39 | $11.67 | $11.03 | 953,000 | |
| $11.47 | -0.03 | -0.3% | $11.69 | $11.93 | $11.32 | 1,411,200 | |
| $11.50 | -0.24 | -2.0% | $11.79 | $11.81 | $11.31 | 1,140,400 | |
| $11.74 | +0.08 | +0.7% | $11.57 | $11.93 | $11.39 | 811,000 | |
| $11.66 | -0.23 | -1.9% | $11.89 | $11.92 | $11.53 | 1,532,900 | |
| $11.89 | -0.63 | -5.0% | $12.35 | $12.42 | $11.38 | 1,871,600 | |
| $12.52 | -1.69 | -11.9% | $14.29 | $14.39 | $12.06 | 2,140,800 | |
| $14.21 | +0.57 | +4.2% | $13.75 | $14.29 | $13.63 | 930,000 | |
| $13.64 | -0.41 | -2.9% | $14.13 | $14.23 | $13.55 | 1,222,200 | |
| $14.05 | -0.01 | -0.1% | $14.15 | $14.44 | $13.92 | 4,049,700 | |
| $14.06 | -0.05 | -0.4% | $14.49 | $14.66 | $13.77 | 1,401,600 | |
| $14.11 | +0.20 | +1.4% | $14.00 | $14.55 | $13.87 | 2,622,000 | |
| $13.91 | -0.65 | -4.5% | $14.71 | $14.71 | $13.38 | 1,552,500 | |
| $14.56 | +0.31 | +2.2% | $14.49 | $14.96 | $14.30 | 1,094,900 | |
| $14.25 | -0.70 | -4.7% | $15.21 | $15.45 | $14.09 | 1,378,200 | |
| $14.95 | -0.10 | -0.7% | $14.83 | $15.07 | $14.16 | 1,494,600 | |
| $15.05 | -0.85 | -5.3% | $15.82 | $16.17 | $14.96 | 1,633,100 | |
| $15.90 | +0.38 | +2.4% | $15.62 | $16.08 | $15.13 | 918,200 | |
| $15.52 | +0.93 | +6.4% | $14.49 | $15.96 | $14.28 | 1,495,300 | |
| $14.59 | -0.46 | -3.1% | $13.96 | $15.39 | $13.60 | 5,527,000 | |
| $15.05 | +0.23 | +1.6% | $14.79 | $15.29 | $14.40 | 2,214,700 | |
| $14.82 | +1.09 | +7.9% | $13.88 | $15.03 | $13.09 | 1,972,500 | |
| $13.73 | -0.84 | -5.8% | $14.58 | $14.70 | $13.49 | 1,437,100 | |
| $14.57 | -0.49 | -3.3% | $14.86 | $15.13 | $14.37 | 840,700 | |
| $15.06 | -1.02 | -6.3% | $16.09 | $16.33 | $14.94 | 1,552,500 | |
| $16.08 | -1.76 | -9.9% | $17.72 | $17.80 | $16.01 | 1,392,100 | |
| $17.84 | +1.44 | +8.8% | $16.75 | $18.33 | $16.75 | 1,203,100 | |
| $16.40 | -0.88 | -5.1% | $17.27 | $17.41 | $16.05 | 1,177,800 | |
| $17.28 | +0.26 | +1.5% | $17.26 | $17.71 | $17.00 | 957,400 | |
| $17.02 | -0.32 | -1.8% | $17.16 | $17.45 | $16.72 | 903,900 |
- Ticker
- NASDAQ:CLYM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest deck · Nov 5, 2026
Investor Presentation (November 2026)
Investor deck · 60 slides
Latest news
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 5, 2026
Closed $8.87 (-4.9%) on Nov 5, 2026
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
Nov 4, 2026
Closed $9.33 (-4.3%) on Nov 4, 2026
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 2, 2026
Closed $9.74 (-5.0%) on Nov 2, 2026
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Oct 24, 2026
Closed $8.81 (-13.5%) on Oct 26, 2026
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
Oct 23, 2026
Closed $8.81 (-13.5%) on Oct 26, 2026
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Oct 2, 2026
Closed $10.94 (-1.2%) on Oct 2, 2026
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
Sep 3, 2026
Closed $14.59 (-3.1%) on Sep 3, 2026
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 6, 2026
Closed $14.00 (+12.3%) on Aug 6, 2026
Climb Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 44 in all · newest Nov 5, 2026 · oldest 2024
- Decks
- 12 decks · latest Nov 5, 2026
Where Climb Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CLYM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CLYM | BOATS | United States | USD |
Valuation
Price/book 2.4× against a median of 1.6×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $335.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.44
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Climb Bio, Inc. · NASDAQ:CLYM | US$539.8M | US$335.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.44 |
| Ascletis Pharma, Inc. · HKEX:1672 | US$571.3M | US$232.4M | n/a | 765× | n/a | 1.7× | n/a | 0.0× | n/a |
| 4D Molecular Therapeutics, Inc. · NASDAQ:FDMT | US$565.1M | US$277.8M | n/a | 2.9× | n/a | 1.7× | −208.6% | 0.1× | 1.75 |
| Bicara Therapeutics Inc. · NASDAQ:BCAX | US$560.3M | US$118.8M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.37 |
| Lepu Biopharma Co. Ltd. Class H · HKEX:2157 | US$554.8M | US$613.4M | 14.6× | 4.5× | 22.9× | 2.6× | 28.0% | 0.8× | n/a |
| Aclaris Therapeutics, Inc. · NASDAQ:ACRS | US$545.6M | US$431.3M | n/a | 67.4× | n/a | 3.3× | n/a | 0.0× | 1.42 |
| ArriVent BioPharma, Inc. · NASDAQ:AVBP | US$544.1M | US$151.2M | n/a | 30.2× | n/a | 1.4× | n/a | 0.0× | 1.18 |
| Surrozen, Inc. · NASDAQ:SRZN | US$542.5M | US$448.0M | n/a | 42.5× | n/a | n/a | n/a | n/a | 1.64 |
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.7M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Electra Therapeutics, Inc. · NASDAQ:ETRA | US$509.8M | US$107.3M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Median of the others | US$544.9M | US$230.5M | 14.6× | 30.2× | 22.9× | 1.6× | −90.3% | 0.0× | 1.50 |
Forecasts
14 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 28.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.75 · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Aoife Brennan | Board Member, President and Chief Executive Officer |
| Susan Altschuller | Chief Financial Officer |
| Chandra Adams | Senior Vice President, General Counsel |
| Adam Villa | Senior Vice President, Technical Operations |
| Ashley Jones | Senior Vice President, People & Workforce Strategy |
| Edgar Charles | Chief Medical Officer |
| Perrin Wilson | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Douglas E. Williams | Chairman |
| Aoife Brennan | Board Member, President and Chief Executive Officer |
| Bo Cumbo | Board Member |
| Breanna O’Reilly | Board Member |
| Judith Dunn | Board Member |
| Kim Cobleigh Drapkin | Board Member |
| Stephen Thomas | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −4.9% |
| Q2 2026 | Aug 6, 2026 · Before open | +12.3% |
| Q1 2026 | May 7, 2026 · Before open | −2.5% |
| Q4 2025 | Mar 9, 2026 | +2.1% |
| Q3 2025 | Nov 6, 2025 · Before open | +1.6% |
| Q2 2025 | Aug 14, 2025 · Before open | +5.5% |
| Q1 2025 | May 14, 2025 | −5.5% |
| Q4 2024 | Mar 25, 2025 · After close | 0.0% |
| Q3 2024 | Nov 12, 2024 | −13.1% |
| Q2 2024 | Aug 14, 2024 | −2.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 | −3.2% |
| Q4 2023 | Mar 4, 2024 | +4.8% |
| Q3 2023 | Nov 6, 2023 | −1.6% |
| Q2 2023 | Sep 11, 2023 | +2.3% |
| Q1 2023 | May 11, 2023 · After close | −4.2% |
| Q4 2022 | Mar 6, 2023 | +3.2% |
| Q3 2022 | Nov 14, 2022 · Before open | −3.3% |
| Q2 2022 | Aug 15, 2022 · Before open | −2.0% |
| Q1 2022 | May 16, 2022 | −11.1% |
| Q4 2021 | Mar 7, 2022 · After close | +1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 60 slides | Nov 5, 2026 |
| Investor Presentation (October 2026) | Investor deck | 59 slides | Oct 26, 2026 |
| Technical Presentation (September 2026) | Technical | 26 slides | Sep 3, 2026 |
| Investor Presentation (September 2026) | Investor deck | 57 slides | September 2026 |
| Technical Presentation (May 2026) | Technical | 51 slides | May 5, 2026 |
| Technical Presentation (September 2025) | Technical | 46 slides | Sep 29, 2025 |
| Eliem Therapeutics — Merger or Acquisition (April 2024) | Merger or acquisition | 18 slides | Apr 11, 2024 |
| Eliem Therapeutics — Investor Presentation (May 2023) | Investor deck | 20 slides | May 11, 2023 |
| Eliem Therapeutics — Investor Presentation (November 2022) | Investor deck | 33 slides | Nov 14, 2022 |
| Eliem Therapeutics — Investor Presentation (October 2022) | Investor deck | 24 slides | Oct 5, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Eliem Therapeutics — Investor Presentation (March 2022) | Investor deck | 34 slides | Mar 29, 2022 |
| Eliem Therapeutics — Investor Presentation (November 2021) | Investor deck | 29 slides | Nov 8, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock and pre-funded warrants Announced: about US$110M · US$9.5 a share · Leerink Partners +5 Dealers: Leerink Partners (lead), Piper Sandler (lead), Raymond James, BTIG, Baird, H.C. Wainwright & Co. Buyers: Adage Capital Partners, L.P.; ADAR1 Capital Management; Affinity Asset Advisors, LLC; Ally Bridge Group; Cormorant Asset Management; Driehaus Capital Management; Great Point Partners, LLC; RA Capital Management; Redmile; Sirenia Capital Management LP; Woodline Partners LP | Apr 28, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Eliem Therapeutics, Inc. Priced at US$12.50 a share on Aug 9, 2021.
- Price
- US$12.50 a share
- Shares offered
- 6,400,000 shares of common stock
- Offering size
- US$80 million
- Underwriters' option
- Up to 960,000 more shares
- Underwriters
- SVB Leerink, Evercore ISI, Stifel, Guggenheim Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 12, 2021 |
| Filed publicly | Jul 16, 2021 |
| Amended 4 times | Newest Aug 9, 2021 |
| Shares registered with an exchange | Aug 3, 2021 |
| Declared effective by the SEC | Aug 9, 2021 |
| Final prospectus, with the price | Aug 11, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 11, 2021 |
| EFFECT · Notice that a registration is effective | Aug 9, 2021 |
| S-1MEF · Registration of more shares for the same offering | Aug 9, 2021 |
| S-1/A · Registration statement, amended | Aug 9, 2021 |
| CORRESP · Letter to the SEC | Aug 9, 2021 |
| CORRESP · Letter to the SEC | Aug 9, 2021 |
| FWP · Free writing prospectus | Aug 9, 2021 |
| S-1/A · Registration statement, amended | Aug 9, 2021 |
| CERT · Exchange's certificate of listing | Aug 5, 2021 |
| CORRESP · Letter to the SEC | Aug 5, 2021 |
All 26 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Aug 4, 2021 |
| CORRESP · Letter to the SEC | Aug 4, 2021 |
| CORRESP · Letter to the SEC | Aug 3, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 3, 2021 |
| S-1/A · Registration statement, amended | Aug 3, 2021 |
| UPLOAD · Letter from the SEC | Aug 2, 2021 |
| S-1/A · Registration statement, amended | Aug 2, 2021 |
| CORRESP · Letter to the SEC | Jul 28, 2021 |
| S-1 · Registration statement | Jul 16, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jul 12, 2021 |
| DRS/A · Draft registration statement, amended | Jul 12, 2021 |
| UPLOAD · Letter from the SEC | Jul 6, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 21, 2021 |
| DRS/A · Draft registration statement, amended | Jun 21, 2021 |
| UPLOAD · Letter from the SEC | Jun 9, 2021 |
| DRS · Draft registration statement | May 12, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 11, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 97.0K | ||||||
| Gross profit | -97.0K | ||||||
| Research and development | 46.7M | 14.3M | 15.4M | 26.2M | 23.3M | 8.77M | 4.02M |
| Selling, general and administrative | 21.2M | 16.0M | 24.9M | 18.9M | 12.3M | 2.42M | 677.0K |
| Operating income | -67.9M | -82.0M | -40.3M | -45.1M | -35.7M | -20.9M | -7.45M |
| Depreciation and amortization | 97.0K | 0 | |||||
| EBITDA | -67.8M | -82.0M | |||||
| Income before tax | -59.9M | -73.9M | -35.1M | -45.2M | -47.5M | -20.7M | -6.55M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -59.9M | -73.9M | -35.1M | -45.2M | -47.5M | -20.7M | -6.55M |
| Earnings per share, basic | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -10.49 | -0.56 |
| Earnings per share, diluted | -0.88 | -1.53 | -1.30 | -1.72 | -4.24 | -10.49 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 35.7M | 87.2M | 93.1M | 43.6M | 46.9M | 20.5M | 21.2M |
| Short-term investments | 65.4M | 63.7M | 13.7M | 80.0M | 89.6M | 0 | |
| Receivables | 1.12M | 2.46M | 6.49M | 6.52M | |||
| Current assets | 105.8M | 154.9M | 110.3M | 134.4M | 148.3M | 22.0M | 21.3M |
| Property, plant and equipment | 288.0K | 199.0K | |||||
| Total assets | 167.7M | 217.2M | 110.5M | 135.0M | 173.2M | 24.6M | 21.4M |
| Accounts payable | 2.27M | 705.0K | 66.0K | 750.0K | 1.40M | 1.09M | 647.0K |
| Current liabilities | 6.98M | 4.93M | 2.83M | 6.10M | 6.03M | 3.06M | 783.0K |
| Total debt | 541.0K | 532.0K | 349.0K | 480.0K | |||
| Total liabilities | 7.27M | 5.31M | 2.87M | 6.28M | 6.04M | 3.06M | 783.0K |
| Shareholders' equity | 160.5M | 211.9M | 107.6M | 128.7M | 167.2M | -25.0M | 20.6M |
| Shares outstanding | 47.8M | 67.3M | 27.7M | 26.6M | 26.6M | 3.42M | 11.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -54.4M | -15.6M | -20.6M | -37.4M | -36.1M | -14.1M | -5.01M |
| Capital spending | -186.0K | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -54.5M | -15.6M | -20.6M | -37.4M | -36.1M | -14.1M | -5.01M |
| Cash from investing | 2.83M | -121.1M | 69.0M | 34.4M | -115.0M | 8.08M | |
| Cash from financing | -21.0K | 130.7M | 841.0K | 0 | 177.2M | 4.92M | 26.2M |
| Change in cash | -51.5M | -5.88M | 49.5M | -3.34M | 26.4M | -736.0K | 21.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Nov 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 12, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 12, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 10, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jun 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jun 5, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 5, 2026 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jun 4, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 29, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 8-K · Current report | May 5, 2026 | Current report | SEC |
| D | May 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 28, 2026 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 3, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 31, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 17, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 18, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | May 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 23, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| 424B5 · Prospectus | Mar 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Nov 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 19, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 12, 2024 | Insider trade | SEC |
| S-3 · Registration statement | Nov 12, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2024 | Results | SEC |
| 8-K · Current report | Oct 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 27, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 26, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 16, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Jul 24, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 23, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Jul 23, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 19, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 19, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jul 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2024 | Insider trade | SEC |
| S-3 · Registration statement | Jul 12, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jul 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| D | Jul 2, 2024 | Other filings | SEC |
| D | Jul 2, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Jul 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 26, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 14, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 12, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 12, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 6, 2024 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jun 4, 2024 | Annual report | SEC |
| DEFM14A | Jun 4, 2024 | Meeting notice | SEC |
| PREM14A | May 17, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | May 17, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | May 17, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | May 7, 2024 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 12, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 11, 2024 | Material contract | SEC |
| 4 · Change in ownership | Apr 8, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 18, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 17, 2023 | Big-stake notice | SEC |
This page holds 200 of 326 filings. Open Filings
Cap table
Built by 6ix from Climb Bio, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 58,738,178
- Fully diluted
- 58,738,178
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 58,738,178 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 58,738,178 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Aug 9, 2021 |
| Robert Azelby Other companies: Tango Therapeutics, Inc. (Chairman; Former President and CEO, Eliem Therapeutics, Inc. · Since at least Jun 19, 2026); Autolus Therapeutics plc (Director · Since at least Mar 18, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Cardinal Health, Inc. (Director · Since at least Mar 1, 2024); ADC Therapeutics SA (Director · Since at least Jan 2, 2024); Aduro Biotech Inc (Director · Apr 10, 2023 – Aug 11, 2023 · Past); Immunomedics Inc (Director · Feb 26, 2020 – Oct 23, 2020 · Past); Clovis Oncology Inc (Director · Oct 11, 2018 – Jun 10, 2021 · Past); Alder BioPharmaceuticals Inc (President and CEO, Director · Jun 13, 2018 – Oct 22, 2019 · Past); Cascadian Therapeutics Inc (Director · Mar 31, 2017 – Mar 9, 2018 · Past); Juno Therapeutics Inc (EVP & Chief Commercial Officer · Nov 1, 2015 – Mar 5, 2018 · Past) | President & CEO, Director · Aug 9, 2021 – Oct 31, 2022 · Past |
| Alexander Cumbo Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Vor Biopharma Inc. (Chair of the Compensation Committee · Since at least Jul 16, 2025); Solid Biosciences Inc. (President and CEO, Director · Since at least Dec 2, 2022); Verve Therapeutics Inc (Director · Since at least Jun 9, 2022); Ra Pharmaceuticals Inc (Director · Nov 14, 2018 – Apr 2, 2020 · Past); Sarepta Therapeutics, Inc. (EVP, Chief Commercial Officer · Mar 5, 2018 – Feb 28, 2020 · Past) | Director · Since at least Mar 28, 2025 |
| Erin Lavelle Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past) | COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past |
| Leone Patterson Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Apr 3, 2025); Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Nkarta, Inc. (Director · Since at least Jun 8, 2022); Tenaya Therapeutics, Inc. (Chief Fin. and Bus. Officer · Feb 15, 2023 – Feb 23, 2024 · Past) | Director · May 19, 2022 – May 19, 2022 · Past |
| Aoife Brennan Other companies: Xilio Therapeutics, Inc. (Director · Since at least Jun 13, 2024); Kyntra Bio, Inc. (Director · May 26, 2021 – Jun 5, 2024 · Past); Synlogic Inc (President and CEO, Director · Mar 10, 2021 – Nov 10, 2023 · Past) | President and CEO, Director · Since at least Jun 27, 2024 |
| Kimberlee C. Drapkin Other companies: Kineta Inc. (Director · Since at least Jun 23, 2025); LENZ Therapeutics, Inc. (Director · Since at least Jun 11, 2025); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 4, 2025) | Director · Since at least Mar 28, 2025 |
| Bo Cumbo Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Solid Biosciences Inc. (President and CEO · Since at least Jun 2, 2026) | Board Member · Since at least May 14, 2025 |
| Brett Kaplan Other companies: Compass Therapeutics, Inc. (Director · Sep 10, 2020 – Feb 18, 2022 · Past); Prevail Therapeutics Inc (Chief Financial Officer · Jun 19, 2019 – Jan 22, 2021 · Past) | Chief Operating Officer · Aug 26, 2024 – Jan 13, 2025 · Past |
| James B. Bucher Other companies: Zentalis Pharmaceuticals, Inc. (Chief Legal Officer and Corporate Secretary · Since at least Aug 26, 2025); Harpoon Therapeutics Inc (Chief Legal Officer · Dec 21, 2023 – Mar 11, 2024 · Past) | EVP and General Counsel · Oct 31, 2022 – Oct 31, 2022 · Past |
All 24 people
| Person | Seat |
|---|---|
| Cindy Driscoll Other companies: Dianthus Therapeutics, Inc. (See Remarks · Jun 20, 2018 – Oct 1, 2020 · Past) | Senior Vice President, Finance · Since at least Jun 17, 2025 |
| Kim Cobleigh Drapkin Other companies: Acumen Pharmaceuticals, Inc. (Biotechnology Executive · Since at least Jun 5, 2026) | Board Member · Since at least May 14, 2025 |
| Adam Joseph Rosenberg | Director · Aug 9, 2021 – Jun 26, 2024 · Past |
| Adam Villa | Senior Vice President, Technical Operations · Since at least Nov 6, 2025 |
| Ashley Jones | Senior Vice President, People & Workforce Strategy · Since at least Nov 6, 2025 |
| Breanna O’Reilly | Board Member · Since at least Aug 6, 2026 |
| Chandra Adams | Senior Vice President, General Counsel · Since at least Nov 5, 2026 |
| Douglas E. Williams | Chairman · Since at least Aug 19, 2025 |
| Edgar Charles | Chief Medical Officer · Since at least Jun 11, 2026 |
| Judith Dunn | Board Member · Since at least Nov 5, 2026 |
| Perrin Wilson | Chief Business Officer · Since at least May 14, 2025 |
| Stephen Thomas | Director · Since at least Sep 15, 2026 |
| Susan Altschuller | Chief Financial Officer · Since at least Nov 6, 2025 |
| Valerie Morisset | EVP, R&D AND CSO · Oct 31, 2022 – Jul 19, 2024 · Past |
Log in to ask 6ix AI your own questions about Climb Bio, Inc.